Phaseline

Targets › AFP

AFP (Alpha-fetoprotein): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Aug 2027.

Binds copper, nickel, and fatty acids as well as, and bilirubin less well than, serum albumin. Only a small percentage (less than 2%) of the human AFP shows estrogen-binding properties. (UniProt, P02771)

Open in Phaseline: the race on AFP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Ruiliyuan BiotechnologyHRYZ-T102 TCR-T Cell
AFP-specific T cell receptor (TCR) engineered T cells
AFPPhase 1Hepatic Cell CarcinomaAug 2027

Conditions

Hepatic Cell Carcinoma (1)

Modalities

other (1)

Companies

Shanghai Ruiliyuan Biotechnology (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.